In this episode of Meeting Mic, we bring you the highlights and insights from the San Antonio Breast Cancer Symposium 2024, as well as Healio’s top headlines from the meeting.

Judy Garber, MD, MPH, chief of the division of cancer genetics and prevention at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, reviews results of the OlympiA trial. :25

Raza Hoda, MD, a pathologist at Cleveland Clinic and assistant professor of pathology at Cleveland Clinic Lerner College of Medicine, discusses results from the DESTINY-Breast04 and DESTINY-Breast06 trials. 1:55

Shimoli Barot, MD, medical oncologist at Cleveland Clinic Cancer Institute, examines the results of a study observing exceptional treatment response in patients with metastatic breast cancer. 6:02

Eleonora Teplinsky further discusses results of the COMET trial. 10:38

Jennifer A. Ligibel discusses an overview analysis looking at the relationship between body mass index at the time of breast cancer diagnosis and distant recurrence. 19:27

Read the full coverage here:

VIDEO: OlympiA trial shows ‘continued benefit’ in breast cancer survival

VIDEO: Study investigates HER2-low, ultralow eligibility for trastuzumab deruxtecan

VIDEO: Study investigates exceptional treatment response in metastatic breast cancer

Active monitoring safe for some patients with low-risk ductal carcinoma in situ

Source: Hwang ES, et al. Abstract GS2-05. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.

Terminated study’s ‘challenges’ may guide future trials of MRD-guided breast cancer therapy

Source: Turner N, et al. Abstract GS3-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.

Obesity elevates risk for distant recurrence, mortality in early-stage breast cancer

Source: Pan H, et al. Abstract GS2-09. Presented at: San Antonio Breast Cancer Symposium; Dec. 10-13, 2024; San Antonio.

Disclosures:

Barot reports no relevant financial disclosures.

Garber reports no relevant financial disclosures.

Hoda reports no relevant financial disclosures.

Teplinsky reports no relevant financial disclosures.